📰 Exact Sciences News
Page 46 - Exact Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Exact Sciences. Real-time updates on events, politics, business and more.
June 21, 2023
Edmonds Duncan Registered Investment Advisors LLC bought a new position in shares of Exact Sciences Co. (NASDAQ:EXAS – Get Rating) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 3,352 shares of the medical research company’s stock, valued at approximately $227,000. A number of […]
June 21, 2023
Exact Sciences (NASDAQ:EXAS) shares rose in Wednesday pre-market trading after the molecular diagnostics company specializing in the detection of...
June 20, 2023
CareDx (NASDAQ:CDNA – Get Rating) and Exact Sciences (NASDAQ:EXAS – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings. Profitability This table compares CareDx and Exact Sciences’ net margins, return […]
June 20, 2023
Exact Sciences Co. (NASDAQ:EXAS – Get Rating) reached a new 52-week high during trading on Tuesday . The stock traded as high as $95.65 and last traded at $94.19, with a volume of 419660 shares trading hands. The stock had previously closed at $93.42. Analyst Upgrades and Downgrades A number of analysts have commented on […]
June 20, 2023
Colorectal Cancer Screening Market: By End user (Hospitals, Diagnostic laboratories and Others); By Screening Test (Flexible Sigmoidoscopy, Stool-Based...
June 20, 2023
Exact Sciences Corp (NASDAQ: EXAS) shares are rising in extended trading Tuesday after the cancer screening and diagnostics company said its Cologuard test demonstrated 94% sensitivity for 
June 20, 2023
Exact Sciences said Tuesday the company's next-generation Cologuard outperformed the original test. The results could stoke EXAS stock. The post Why Exact…
June 20, 2023
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced positive top-line results...
June 20, 2023
Exact Sciences said Tuesday the company's next-generation Cologuard outperformed the original test. The results stoked EXAS stock.
June 18, 2023
Exact Sciences Co. (NASDAQ:EXAS – Get Rating) has received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target […]